Contingency Management to Promote Smoking Abstinence in Cancer Patients

促进癌症患者戒烟的应急管理

基本信息

项目摘要

PROJECT SUMMARY There is a high incidence of tobacco use among patients with cancer. Many are unable to quit smoking before surgery, and relapse rates are high among those who are able to abstain after the initial cancer diagnosis. Tobacco use is linked to serious complications with treatment, including increased problems with wound healing after surgery. Contingency management, a behavioral intervention in which abstinence is reinforced (typically with monetary incentives), has shown promise as an intervention for smoking. In our preliminary work, we designed a contingency management protocol for pre-surgical cancer patients. A pilot study was conducted to generate an effect size for smoking cessation at the time of surgery (7-day point prevalence abstinence), and a secondary aim of creating an effect size for long-term abstinence at 3 months post-surgery. Patients (N=40) were randomized to receive either: Standard Care + Monitoring (SC; i.e., 3-6 counseling sessions + nicotine replacement therapy [NRT] + monitoring breath CO 3 times per week with no contingencies; N=19) or CM (i.e., 3-6 counseling sessions + NRT + monetary payment delivered contingent on a negative breath CO; N=21). In the CM group 52% (11/21) of the patients were abstinent for 7 days prior to surgery compared to 16% (3/19) of the patients in SC (adjusted RR=3.3, CI: 1.1-9.7, p=0.03). At the 3-month follow-up, 43% (9/21) of CM patients remained abstinent compared to 5% (1/19) in the SC group (adjusted RR=8.6, CI: 1.5-49.4, p=0.02). For the present study, we propose a powered, large scale (N=282) smoking cessation clinical trial to test a CM intervention for cancer patients. The intervention will mirror our prior work, focusing on patients who are undergoing surgery for their cancer. No studies have evaluated a CM intervention with smokers who have a life-threatening illness. However, our pilot data with pre-surgical cancer patients who smoke has shown that this may be a promising intervention with cancer patients. We hypothesize that this highly effective treatment, by promoting high rates of smoking cessation, will also be associated with better surgical outcomes. Interventions for smoking cessation prior to cancer surgery are understudied and a valuable tool in promoting improved surgical outcomes.
项目摘要 癌症患者吸烟的发生率很高。许多人以前无法戒烟 在初次癌症诊断后能够戒酒的人中,复发率很高。 烟草使用与治疗的严重并发症有关,包括伤口问题的增加 手术后愈合。应急管理,一种加强禁欲的行为干预 (通常以金钱奖励),已显示出作为吸烟干预措施的前景。在我们的初步调查中 工作,我们设计了一个应急管理协议,为术前癌症患者。了一项初步研究 进行手术时戒烟的效应量(7天点患病率 禁欲),以及在术后3个月时创建长期禁欲的效应量的次要目的。 患者(N=40)随机接受:标准护理+监测(SC;即,3-6辅导 治疗+尼古丁替代疗法[NRT] +监测呼吸CO,每周3次,无 意外事件; N=19)或CM(即,3-6咨询会议+ NRT +视情况提供的货币支付 阴性呼吸CO; N=21)。在CM组中,52%(11/21)的患者在给药前禁欲7天 外科手术,而SC组患者为16%(3/19)(调整后RR=3.3,CI:1.1-9.7,p=0.03)。在3个月 随访时,43%(9/21)的CM患者保持禁欲,而SC组为5%(1/19)(调整后 RR=8.6,CI:1.5-49.4,p=0.02)。在本研究中,我们提出了一个动力,大规模(N=282)吸烟 停止临床试验,以测试癌症患者的CM干预。干预将反映我们之前的工作, 关注那些正在接受癌症手术的病人。没有研究评价CM干预 患有危及生命的疾病的吸烟者。然而,我们对手术前癌症患者的初步数据显示, 吸烟表明,这可能是一个有希望的干预癌症患者。我们假设这 高效的治疗,通过促进高戒烟率,也将与更好的 手术结果。癌症手术前戒烟的干预措施尚未得到充分研究, 促进改善手术结果的有价值的工具。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Benjamin Andrew Toll其他文献

Benjamin Andrew Toll的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Benjamin Andrew Toll', 18)}}的其他基金

Contingency Management to Promote Smoking Abstinence in Cancer Patients
促进癌症患者戒烟的应急管理
  • 批准号:
    10641849
  • 财政年份:
    2020
  • 资助金额:
    $ 51.09万
  • 项目类别:
Contingency Management to Promote Smoking Abstinence in Cancer Patients
促进癌症患者戒烟的应急管理
  • 批准号:
    10431880
  • 财政年份:
    2020
  • 资助金额:
    $ 51.09万
  • 项目类别:
Contingency Management to Promote Smoking Abstinence in Cancer Patients
促进癌症患者戒烟的应急管理
  • 批准号:
    10027457
  • 财政年份:
    2020
  • 资助金额:
    $ 51.09万
  • 项目类别:
Gain-framed Messages and NRT Sampling to Promote Smoking Cessation in Lung Cancer Screening Programs
增益框架信息和 NRT 采样促进肺癌筛查项目中的戒烟
  • 批准号:
    9539986
  • 财政年份:
    2016
  • 资助金额:
    $ 51.09万
  • 项目类别:
Gain-framed Messages and NRT Sampling to Promote Smoking Cessation in Lung Cancer Screening Programs
增益框架信息和 NRT 采样促进肺癌筛查项目中的戒烟
  • 批准号:
    9349467
  • 财政年份:
    2016
  • 资助金额:
    $ 51.09万
  • 项目类别:
Gain-framed Messages and NRT Sampling to Promote Smoking Cessation in Lung Cancer Screening Programs
增益框架信息和 NRT 采样促进肺癌筛查项目中的戒烟
  • 批准号:
    9162164
  • 财政年份:
    2016
  • 资助金额:
    $ 51.09万
  • 项目类别:
Gain-framed Messages and NRT Sampling to Promote Smoking Cessation in Lung Cancer Screening Programs
增益框架信息和 NRT 采样促进肺癌筛查项目中的戒烟
  • 批准号:
    10318095
  • 财政年份:
    2016
  • 资助金额:
    $ 51.09万
  • 项目类别:
Gain-framed Messages and NRT Sampling to Promote Smoking Cessation in Lung Cancer Screening Programs
增益框架信息和 NRT 采样促进肺癌筛查项目中的戒烟
  • 批准号:
    10088417
  • 财政年份:
    2016
  • 资助金额:
    $ 51.09万
  • 项目类别:
Quit4hlth: Enhancing Tobacco and Cancer Control Through Framed Text Messages
Quit4hlth:通过框架短信加强烟草和癌症控制
  • 批准号:
    8957487
  • 财政年份:
    2015
  • 资助金额:
    $ 51.09万
  • 项目类别:
Quit4hlth: Enhancing Tobacco and Cancer Control Through Framed Text Messages
Quit4hlth:通过框架短信加强烟草和癌症控制
  • 批准号:
    9139420
  • 财政年份:
    2015
  • 资助金额:
    $ 51.09万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 51.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了